MENU
+Compare
AVIR
Stock ticker: NASDAQ
AS OF
Jul 25 closing price
Price
$3.90
Change
+$0.16 (+4.28%)
Capitalization
333.76M

AVIR Atea Pharmaceuticals Forecast, Technical & Fundamental Analysis

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections... Show more

Industry: #Biotechnology
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for AVIR with price predictions
Jul 25, 2025

Aroon Indicator for AVIR shows an upward move is likely

AVIR's Aroon Indicator triggered a bullish signal on July 21, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 134 similar instances where the Aroon Indicator showed a similar pattern. In of the 134 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 54 cases where AVIR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 25, 2025. You may want to consider a long position or call options on AVIR as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for AVIR moved above the 200-day moving average on July 16, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where AVIR advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .

AVIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Moving Average Convergence Divergence Histogram (MACD) for AVIR turned negative on July 15, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVIR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.812) is normal, around the industry mean (18.053). P/E Ratio (0.000) is within average values for comparable stocks, (59.920). AVIR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.580). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (280.104).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AVIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

AVIR is expected to report earnings to rise 3.62% to -41 cents per share on August 06

Atea Pharmaceuticals AVIR Stock Earnings Reports
Q2'25
Est.
$-0.41
Q1'25
Beat
by $0.01
Q4'24
Missed
by $0.05
Q3'24
Beat
by $0.06
Q2'24
Beat
by $0.18
The last earnings report on May 12 showed earnings per share of -40 cents, beating the estimate of -40 cents. With 447.74K shares outstanding, the current market capitalization sits at 333.76M.
A.I. Advisor
published General Information

General Information

a developer of vaccines

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
225 Franklin Street
Phone
+1 857 284-8891
Employees
75
Web
https://www.ateapharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DASTY35.080.63
+1.83%
Dassault Systemes SA
RELV2.59N/A
N/A
Reliv International, Inc.
ILPMF2.33N/A
N/A
Permanent TSB Group Holdings plc
CDPYF33.12-0.36
-1.06%
Canadian Apartment Properties Real Estate Investment Trust
WEGYF0.48-0.01
-1.34%
WESTBRIDGE RENEWABLE ENERGY CORP.

AVIR and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AVIR has been loosely correlated with AXON. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AVIR jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVIR
1D Price
Change %
AVIR100%
+4.28%
AXON - AVIR
46%
Loosely correlated
+3.63%
XENE - AVIR
46%
Loosely correlated
-2.29%
IDYA - AVIR
44%
Loosely correlated
-1.33%
ZNTL - AVIR
43%
Loosely correlated
N/A
IMNM - AVIR
42%
Loosely correlated
-3.29%
More